Genomictree Inc. (KOSDAQ:228760)
11,180
-110 (-0.97%)
Sep 1, 2026, 3:30 PM KST
Genomictree Revenue
Genomictree had revenue of 842.32M KRW in the quarter ending June 30, 2026, a decrease of -51.06%. This brings the company's revenue in the last twelve months to 2.95B, down -17.13% year-over-year. In the year 2025, Genomictree had annual revenue of 3.76B with 59.17% growth.
Revenue (ttm)
2.95B
Revenue Growth
-17.13%
P/S Ratio
93.98
Revenue / Employee
n/a
Employees
n/a
Market Cap
276.90B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 3.76B | 1.40B | 59.17% |
| Dec 31, 2024 | 2.36B | -1.06B | -30.89% |
| Dec 31, 2023 | 3.42B | -26.45B | -88.56% |
| Dec 31, 2022 | 29.87B | 24.73B | 481.09% |
| Dec 31, 2021 | 5.14B | 3.90B | 314.87% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| GC Corp. | 2.49T |
| Bioneer | 338.01B |
| Medy-Tox | 251.08B |
| GC Cell | 162.00B |
| MEDIPOST | 74.84B |
| HLB Therapeutics | 64.45B |
| SillaJen | 10.92B |
| GI Innovation | 5.63B |